News | Heart Valve Technology | May 18, 2016

Implantation of Rapid Deployment Aortic Valve Found Durable, Safe and Effective

TRANSFORM Trial shows Edwards Intuity valve system shortens duration of interrupted blood flow and heart stoppage during surgery

RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting

May 18, 2016 — The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic valve replacement (RDAVR) system for patients with severe aortic stenosis. Results of the study were presented at the 96th American Association for Thoracic Surgery (AATS) Annual Meeting,

Investigators showed that more than 96 percent of TRANSFORM patients had survived after one year and only 0.2 percent required reoperation. Cardiac function improved in 73 percent. Compared to conventional treatment, this procedure required significantly less cross-clamp and cardiopulmonary bypass times, even when smaller incisions were used.

The investigational RDAVR system used in the TRANSFORM trial, the Edwards Intuity valve system, was developed to combine the ease-of-use functionality of rapid deployment valve fixation with the proven long-term durability of the Perimount Magna Ease valve. The device tested included new innovations such as a polyester sealing cloth and a balloon-expandable stainless steel frame.

“The Edwards Intuity valve system reduces operative complexity by allowing the valve to be placed using only three guiding sutures,” explained Walter Randolph Chitwood, Jr., M.D., founder of the East Carolina Heart Institute of East Carolina University, Greenville, N.C. “The TRANSFORM clinical trial shows that this device reduces the duration that the heart is stopped. By simplifying the steps to implant the aortic valve, surgeons are able to use smaller, less invasive incisions. This benefits patients by causing less pain and promoting faster recovery.”

The trial was a prospective, nonrandomized, single-arm clinical trial that enrolled patients in 29 medical centers. Enrolled patients were at least 18 years of age and required aortic valve replacement. Of 889 enrolled patients, 839 received an Edwards Intuity. The study evaluated both the first-generation (n=109) and the second-generation Edwards Intuity Elite (n=730). The mean age was 73.5 years; 52.2 percent were categorized as New York Heart Association (NYHA) Class II and 30.5 percent as NYHA Class III heart failure. Some patients also underwent other procedures at the same time, such as coronary artery bypass grafting (28 percent) and atrial ablation (5.5 percent). Three surgical approaches were utilized. Almost 60 percent required full sternotomy, 33 percent required mini upper sternotomy and 8 percent right anterior thoracotomy.

Thirty-day mortality was 0.8 percent, and 96.4 percent were alive at the end of the first year post-surgery. At 30 days, the reoperation rate was 0.2 percent and 0.1 percent required valve removal. Functionally, 73 percent showed improvement in their NYHA heart failure classification, while 23.6 percent were unchanged, and 3.3 percent worsened at one year.

In terms of complications, 3.5 percent experienced thromboembolism and 1.3 percent had major bleeding within 30 days. The investigators observed that the rates of leakage around the valves (1.1 percent with leakage and 0.2 percent with major leakage) were clinically acceptable for this type of procedure. By two years, 90.3 percent of patients had no or trivial leaks and 9.7 percent had mild leakage.

For all three surgical approaches, interruption of the normal circulation to accomplish the aortic replacement was significantly less than required by conventional surgery as reported in the STS Adult Cardiac Surgery Database. For example, for patients undergoing full sternotomy, average time for aortic cross clamping went from 76.4 minutes to 49.3 minutes, and cardiopulmonary bypass time was reduced from 104.2 minutes to 69.2 minutes with INTUITY. Similar time savings were observed in patients who underwent smaller incisions with mini sternotomy.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init